Serum cytokines associated with severity and complications of kala-azar

Pathogens and Global Health

Volumn 107, Issue 2, 2013, Pages 78-87

  Costa, Dorcas L ^a,b   Rocha, Regina L ^c   Carvalho, Rayssa M A ^d   Lima Neto, Adelino S ^a,b   Harhay, Michael O ^a   Costa, Carlos Henrique N ^a,b   Barral Neto, Manoel ^d   Barral, Aldina P ^d  

^a FEDERAL UNIVERSITY OF PIAUÍ   (Brazil)

^b Institute of Tropical Medicine 'Natan Portella'   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Cytokines; Disseminated intravascular coagulation; Kala azar; Leishmania infantum; Systemic inflammatory response

Indexed keywords

CYTOKINE; D DIMER; FIBRIN DEGRADATION PRODUCT; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; EDEMA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFANT; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NEWBORN; PRESCHOOL CHILD; THROMBOCYTE COUNT; VISCERAL LEISHMANIASIS; VOMITING;

ADOLESCENT; ADULT; BRAZIL; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; HEMORRHAGE; HIV SEROPOSITIVITY; HUMANS; INFANT; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKIN-8; LEISHMANIASIS, VISCERAL; MALE; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875473148     PISSN: 20477724     EISSN: 20477732     Source Type: Journal    
DOI: 10.1179/2047773213Y.0000000078     Document Type: Article

References (60)

1. Herwaldt BL. Leishmaniasis. Lancet. 1999;354(9185):1191-9.
2. Seaman J, Mercer AJ, Sondorp HE, Herwaldt BL. Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources. Ann Intern Med. 1996;124(7):664-72.
3. Werneck GL, Batista MS, Gomes JR, Costa DL, Costa CH. Prognostic factors for death from visceral leishmaniasis in Teresina, Brazil. Infection. 2003;31(3):174-7.
4. Abdelmoula MS, M'Hamdi Z, Amri F, Tebib N, Ben Turkia H, Ben Dridi MF. [Visceral leishmaniasis in children: prognostic factors]. Tunis Med. 2003;81(8):535-9. French.
5. Collin S DR, Ritmeijer K, Keus K, Melaku Y, Kipngetich S, Davies C. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis. 2004;38(5):612-9.
6. WHO. Control of the leishmaniasis. Technical Report Series 793 Geneve: World Health Organization; 1990.
7. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis. 2004;27(5):305-18.
8. Harhay MO, Olliaro PL, Costa DL, Costa CH. Urban parasitology: visceral leishmaniasis in Brazil. Trends Parasitol. 2011;27(9):403-9.
9. Peruhype-Magalhaes V, Martins-Filho OA, Prata A, Silva Lde A, Rabello A, Teixeira-Carvalho A, et al. Mixed inflammatory/ regulatory cytokine profile marked by simultaneous raise of interferon-gamma and interleukin-10 and low frequency of tumour necrosis factor-alphaz monocytes are hallmarks of active human visceral Leishmaniasis due to Leishmania chagasi infection. Clin Exp Immunol. 2006;146(1):124-32.
10. Sampaio MJ, Cavalcanti NV, Alves JG, Filho MJ, Correia JB. Risk factors for death in children with visceral leishmaniasis. PLoS Negl Trop Dis. 2010;4(11):e877.
11. Costa CH, Werneck GL, Costa DL, Holanda TA, Aguiar GB, Carvalho AS, et al. Is severe visceral leishmaniasis a systemic inflammatory response syndrome? A case control study. Rev Soc Bras Med Trop. 2010;43(4):386-92.
12. Ambalavanan N, Carlo WA, D'Angio CT, McDonald SA, Das A, Schendel D, et al. Cytokines associated with bronchopulmonary dysplasia or death in extremely low birth weight infants. Pediatrics. 2009;123(4):1132-41.
13. Pavare J, Grope I, Kalnins I, Gardovska D. High-mobility group box-1 protein, lipopolysaccharide-binding protein, interleukin-6. and C-reactive protein in children with community acquired infections and bacteraemia: a prospective study. BMC Infect Dis. 2010;10:28.
14. Carson JA, Baltgalvis KA. Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc Sport Sci Rev. 2010;38(4):168-76.
15. Levi M, van der Poll T, Schultz M. Infection and inflammation as risk factors for thrombosis and atherosclerosis. Sem Thromb Hemost. 2012;38(5):506-14.
16. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferongamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75(2):163-89.
17. Rhodes J, Jones DH, Bleehen NM. Increased expression of human monocyte HLA-DR antigens and Fc gamma receptors in response to human interferon in vivo. Clin Exp Immunol. 1983;53(3):739-43.
18. Spruijt NE, Visser T, Leenen LP. A systematic review of randomized controlled trials exploring the effect of immunomodulative interventions on infection, organ failure, and mortality in trauma patients. Crit Care. 2010;14(4):R150.
19. Remick DG. Interleukin-8. Crit Care Med. 2005;33(12 Suppl):S466-7.
20. Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008;4(1):34-42.
21. Prakash D, Fesel C, Jain R, Cazenave PA, Mishra GC, Pied S. Clusters of cytokines determine malaria severity in Plasmodium falciparum-infected patients from endemic areas of Central India. J Infect Dis. 2006;194(2):198-207.
22. de Jong HK, van der Poll T, Wiersinga WJ. The systemic proinflammatory response in sepsis. J Innate Immun. 2010;2(5):422-30.
23. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998;91(10):3527-61.
24. Costa DL. Fatores de prognó stico na leishmaniose visceral: alterações clínicas e laboratoriais associadas àresposta imune, aos distúrbios da coagulação e àmorte. [Doutorado]. Belo Horizonte (MG): Universidade Federal de Minas Gerais; 2009.
25. al-Jurayyan NA, al-Nasser MN, al-Fawaz IM, al Ayed IH, al Herbish AS, al-Mazrou AM, et al. The haematological manifestations of visceral leishmaniasis in infancy and childhood. J Trop Pediatr. 1995;41(3):143-8.
26. Lomtadze ML, Khochava MA, Shalamberidze IA, Shilakadze MA, Dzhokhtaberidze TG. [Functional status of haemostasis system in patients with visceral leishmaniasis]. Georgian Med News. 2005(128):59-62. Russian.
27. Lomtadze ML, Khochava MA, Shalamberidze IA, Kharaishvili VI, Vorob'eva EO. [Study of intravascular coagulation activation markers in patients with visceral leishmaniasis]. Georgian Med News. 2005(124-125):47-50. Russian.
28. Zhang J, Alcaide P, Liu L, Sun J, He A, Luscinskas FW, et al. Regulation of endothelial cell adhesion molecule expression by mast cells, macrophages, and neutrophils. PLoS ONE. 2011;6(1):e14525.
29. Lin WC, Lin CF, Chen CL, Chen CW, Lin YS. Prediction of outcome in patients with acute respiratory distress syndrome by bronchoalveolar lavage inflammatory mediators. Exp Biol Med (Maywood). 2010;235(1):57-65.
30. Suffredini AF, Fantuzzi G, Badolato R, Oppenheim JJ, O'Grady NP. New insights into the biology of the acute phase response. J Clin Immunol. 1999;19(4):203-14.
31. Grignani G, Maiolo A. Cytokines and hemostasis. Haematologica. 2000;85(9):967-72.
32. Duarte MI, Corbett CE. Histopathological patterns of the liver involvement in visceral leishmaniasis. Rev Inst Med Trop Sao Paulo. 1987;29(3):131-6.
33. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther. 2006;8Suppl 2: S3.
34. Levi M, ten Cate H, van der Poll T. Endothelium: interface between coagulation and inflammation. Crit Care Med. 2002;30(5 Suppl):S220-4.
35. Alonso DP, Ferreira AF, Ribolla PE, de Miranda Santos IK, do Socorro Pires e Cruz M, Aecio de Carvalho F, et al. Genotypes of the mannan-binding lectin gene and susceptibility to visceral leishmaniasis and clinical complications. J Infect Dis. 2007;195(8):1212-7.
36. Endo Y, Nakazawa N, Iwaki D, Takahashi M, Matsushita M, Fujita T. Interactions of ficolin and mannose-binding lectin with fibrinogen/fibrin augment the lectin complement pathway. J Innate Immun. 2010;2(1):33-42.
37. Gulla KC, Gupta K, Krarup A, Gal P, Schwaeble WJ, Sim RB, et al. Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot. Immunology. 2010;129(4):482-95.
38. Sprong T, Mollnes TE, Neeleman C, Swinkels D, Netea MG, van der Meer JW, et al. Mannose-binding lectin is a critical factor in systemic complement activation during meningococcal septic shock. Clin Infect Dis. 2009;49(9):1380-6.
39. Kager PA, Rees PH. Haematological investigations in visceral leishmaniasis. Trop Geogr Med. 1986;38(4):371-9.
40. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101(7):2461-3.
41. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113(9):1271-6.
42. Jakubowski AA, Casper ES, Gabrilove JL, Templeton MA, Sherwin SA, Oettgen HF. Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer. J Clin Oncol. 1989;7(3):298-303.
43. Verma S, Kumar R, Katara GK, Singh LC, Negi NS, Ramesh V, et al. Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasis. PLoS ONE. 2010;5(4):e10107.
44. Gautam S, Kumar R, Maurya R, Nylen S, Ansari N, Rai M, et al. IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. J Infect Dis. 2011;204(7):1134-7.
45. Conti P, Kempuraj D, Kandere K, Di Gioacchino M, Barbacane RC, Castellani ML, et al. IL-10, an inflammatory/ inhibitory cytokine, but not always. Immunol Lett. 2003;86(2):123-9.
46. Gear AR, Camerini D. Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation. 2003;10(3-4):335-50.
47. Nylen S, Sacks D. Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol. 2007;28(9):378-84.
48. Ansari NA, Kumar R, Gautam S, Nylen S, Singh OP, Sundar S, et al. IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis. J Immunol. 2011;186(7):3977-85.
49. Bacellar O, Oliveira A, Jr, Jeronimo S, Carvalho EM. IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. Cytokine. 2000;12(8):1228-31.
50. Cai B, Deitch EA, Ulloa L. Novel insights for systemic inflammation in sepsis and hemorrhage. Mediators Inflamm. 2010;2010:642462.
51. Ward NS, Casserly B, Ayala A. The compensatory antiinflammatory response syndrome (CARS) in critically ill patients. Clin Chest Med. 2008;29(4):617-25, viii.
52. Devignot S, Sapet C, Duong V, Bergon A, Rihet P, Ong S, et al. Genome-wide expression profiling deciphers host responses altered during dengue shock syndrome and reveals the role of innate immunity in severe dengue. PLoS ONE. 2010; 5(7):e11671.
53. Wagenaar JF, Goris MG, Sakundarno MS, Gasem MH, Mairuhu AT, de Kruif MD, et al. What role do coagulation disorders play in the pathogenesis of leptospirosis? Trop Med Int Health. 2007;12(1):111-22.
54. Bray M. Pathogenesis of viral hemorrhagic fever. Curr Opin Immunol. 2005;17(4):399-403.
55. Clark IA, Budd AC, Alleva LM, Cowden WB. Human malarial disease: a consequence of inflammatory cytokine release. Malar J. 2006;5:85.
56. Frade AF, Oliveira LC, Costa DL, Costa CH, Aquino D, van Weyenbergh J, et al. TGFB1 and IL8 gene polymorphisms and susceptibility to visceral leishmaniasis. Infect Genet Evol. 2011;11(5):912-6.
57. Ratsimandresy RA, Rappaport J, Zagury JF. Anti-cytokine therapeutics: history and update. Curr Pharm Des. 2009;15(17):1998-2025.
58. Webster NR, Galley HF. Immunomodulation in the critically ill. Br J Anaesth. 2009;103(1):70-81.
59. Wheeler DS, Zingarelli B, Wheeler WJ, Wong HR. Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response. Recent Pat Inflamm Allergy Drug Discov. 2009;3(2):96-112.
60. Parker RS, Clermont G. Systems engineering medicine: engineering the inflammation response to infectious and traumatic challenges. J R Soc Interface. 2010;7(48):989-1013.